vs
Apellis Pharmaceuticals, Inc.（APLS）与FULTON FINANCIAL CORP（FULT）财务数据对比。点击上方公司名可切换其他公司
FULTON FINANCIAL CORP的季度营收约是Apellis Pharmaceuticals, Inc.的1.7倍（$336.2M vs $199.9M），FULTON FINANCIAL CORP净利率更高（28.2% vs -29.5%，领先57.7%），FULTON FINANCIAL CORP同比增速更快（4.2% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 0.2%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
富尔顿金融公司是美国的区域性金融服务控股企业，总部位于宾夕法尼亚州兰开斯特市，主要为当地及周边区域提供多元化的金融相关服务，在区域金融市场拥有稳定的业务布局。
APLS vs FULT — 直观对比
营收规模更大
FULT
是对方的1.7倍
$199.9M
营收增速更快
FULT
高出10.1%
-5.9%
净利率更高
FULT
高出57.7%
-29.5%
两年增速更快
APLS
近两年复合增速
0.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $336.2M |
| 净利润 | $-59.0M | $94.8M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | 28.2% |
| 营收同比 | -5.9% | 4.2% |
| 净利润同比 | -62.2% | 1.9% |
| 每股收益（稀释后） | $-0.40 | $0.55 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSFULT
| Q1 26 | — | $336.2M | ||
| Q4 25 | $199.9M | $336.0M | ||
| Q3 25 | $458.6M | $334.6M | ||
| Q2 25 | $178.5M | $324.1M | ||
| Q1 25 | $166.8M | $318.4M | ||
| Q4 24 | $212.5M | $319.6M | ||
| Q3 24 | $196.8M | $317.7M | ||
| Q2 24 | $199.7M | $334.7M |
净利润APLSFULT
| Q1 26 | — | $94.8M | ||
| Q4 25 | $-59.0M | $99.0M | ||
| Q3 25 | $215.7M | $100.5M | ||
| Q2 25 | $-42.2M | $99.2M | ||
| Q1 25 | $-92.2M | $93.0M | ||
| Q4 24 | $-36.4M | $68.6M | ||
| Q3 24 | $-57.4M | $63.2M | ||
| Q2 24 | $-37.7M | $95.0M |
营业利润率APLSFULT
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | 35.7% | ||
| Q3 25 | 48.7% | 38.2% | ||
| Q2 25 | -18.6% | 37.8% | ||
| Q1 25 | -50.0% | 36.1% | ||
| Q4 24 | -12.3% | 27.0% | ||
| Q3 24 | -24.0% | 25.1% | ||
| Q2 24 | -14.7% | 30.8% |
净利率APLSFULT
| Q1 26 | — | 28.2% | ||
| Q4 25 | -29.5% | 29.5% | ||
| Q3 25 | 47.0% | 30.0% | ||
| Q2 25 | -23.6% | 30.6% | ||
| Q1 25 | -55.3% | 29.2% | ||
| Q4 24 | -17.1% | 21.5% | ||
| Q3 24 | -29.2% | 19.9% | ||
| Q2 24 | -18.9% | 28.4% |
每股收益（稀释后）APLSFULT
| Q1 26 | — | $0.55 | ||
| Q4 25 | $-0.40 | $0.53 | ||
| Q3 25 | $1.67 | $0.53 | ||
| Q2 25 | $-0.33 | $0.53 | ||
| Q1 25 | $-0.74 | $0.49 | ||
| Q4 24 | $-0.30 | $0.36 | ||
| Q3 24 | $-0.46 | $0.33 | ||
| Q2 24 | $-0.30 | $0.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $3.5B |
| 总资产 | $1.1B | $32.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSFULT
| Q1 26 | — | — | ||
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — |
股东权益APLSFULT
| Q1 26 | — | $3.5B | ||
| Q4 25 | $370.1M | $3.5B | ||
| Q3 25 | $401.2M | $3.4B | ||
| Q2 25 | $156.3M | $3.3B | ||
| Q1 25 | $164.2M | $3.3B | ||
| Q4 24 | $228.5M | $3.2B | ||
| Q3 24 | $237.1M | $3.2B | ||
| Q2 24 | $264.3M | $3.1B |
总资产APLSFULT
| Q1 26 | — | $32.2B | ||
| Q4 25 | $1.1B | $32.1B | ||
| Q3 25 | $1.1B | $32.0B | ||
| Q2 25 | $821.4M | $32.0B | ||
| Q1 25 | $807.3M | $32.1B | ||
| Q4 24 | $885.1M | $32.1B | ||
| Q3 24 | $901.9M | $32.2B | ||
| Q2 24 | $904.5M | $31.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSFULT
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $304.5M | ||
| Q3 25 | $108.5M | $116.1M | ||
| Q2 25 | $4.4M | $91.7M | ||
| Q1 25 | $-53.4M | $703.0K | ||
| Q4 24 | $19.4M | $416.6M | ||
| Q3 24 | $34.1M | $-22.0M | ||
| Q2 24 | $-8.3M | $157.8M |
自由现金流APLSFULT
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — |
自由现金流率APLSFULT
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — |
资本支出强度APLSFULT
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — |
现金转化率APLSFULT
| Q1 26 | — | — | ||
| Q4 25 | — | 3.08× | ||
| Q3 25 | 0.50× | 1.16× | ||
| Q2 25 | — | 0.92× | ||
| Q1 25 | — | 0.01× | ||
| Q4 24 | — | 6.07× | ||
| Q3 24 | — | -0.35× | ||
| Q2 24 | — | 1.66× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
FULT
暂无分部数据
